In a newly disclosed warning letter, the FDA said Wockhardt's quality-control staff wouldn't allow agency representatives to inspect an aseptic filling area at its troubled Waluj, India, plant. Company employees also appeared to have misled inspectors by discarding data on product testing, the letter said. Report